Preview

Медицинский Совет

Расширенный поиск

Алоглиптин – высокоселективный ингибитор ДПП-4 с фокусом на кардиоваскулярную безопасность

https://doi.org/10.21518/2079-701X-2016-05-104-107

Полный текст:

Аннотация

Сахарный диабет 2-го типа и его хронические осложнения являются одной из глобальных проблем, с которой сталкивается мировое сообщество. Продолжается поиск сахароснижающих препаратов с минимальным риском развития нежелательных явлений, таких как гипогликемия и прибавка массы тела. В данном обзоре обсуждается новый препарат из группы ингибиторов дипептидилпептидазы-4 алоглиптин. Результаты клинической оценки эффективности и безопасности у пациентов с сахарным диабетом 2-го типа в виде монотерапии и в комбинации с другими сахароснижающими препаратами дают дополнительные преимущества в коррекции гипергликемии. 

Об авторах

А. М. Мкртумян
Московский государственный медико-стоматологический университет им. А.И. Евдокимова
Россия
д.м.н., профессор


Л. В. Егшатян
Московский государственный медико-стоматологический университет им. А.И. Евдокимова
Россия


Список литературы

1. Buse JB. Progressive use medical therapies in Type 2 diabetes. Diabetes spectrum, 2000, 13(4): 211-228.

2. IDF Diabetes Atlas, 5th edition, 2011.

3. IDF Diabetes Atlas. 6-th edition. 2013.

4. Economic Costs of Diabetes in the U.S. in 2012. Diabetes Care, 2013, 36(4): 1033-1046.

5. Inzucchi SE, McGuire DK: New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation, 2008, 117: 574-584.

6. Ji LN, Pan CY, Lu JM, Li H, et al. VISION Study Group: Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study. Cardiovasc Diabetol, 2013, 12: 118.

7. Ferrannini E, Fonseca V, Zinman B, Matthews D et al: Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab, 2009, 11(2): 157-166.

8. Iwamoto Y, Tajima N, Kadowaki T, Nonaka K et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab, 2010, 12: 613-622.

9. Takihata M, Nakamura A, Tajima K, Inazumi T et al. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. Diabetes Obes Metab, 2013, 15(5): 455-462.

10. Аметов А.С. Регуляция секреции инсулина в норме и при сахарном диабете 2 типа: роль инкретинов. РМЖ, 2006, 26. 1867-1871.

11. Трунина Е.Н., Петунина Н.А. Чорбинская С.А. Ингибиторы дипептидилпептидазы-4 в лечении сахарного диабета 2 типа. Возможности кардиопротекции. Сахарный диабет, 2011: 2-59.

12. Deacon CF, Nauck MA, Toft-Nielsen M et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes, 1995, 44: 1126-1131.

13. Мкртумян А.М. Алоглиптин – эффективный и безопасный ингибитор дипептидилпептидазы-4 в терапии больных сахарным диабетом 2 типа. Фарматека, 2015, 5. 12-19.

14. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes, 2004, 53: 2181-2189.

15. Gerstein H, Miller M, Byington R et al. Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD). Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008, 358(24): 2545-59.

16. Skyler J, Bergenstal R, Bonow R et al. Intensive glycemic control and the prevention of cardio￾vascular events: implications of the ACCORD, ADVANCE, and VADT: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation, 2009, 119: 351-357.

17. Poucher SM, Francis J, Vickers S et al. Preservation of pancreatic beta cell mass in high fat-fed STZ treated mice by the Dipeptidyl peptidase-4 inhibitors saxagliptin and sitagliptin. EASD, 2010, 567-P.

18. Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin. Drug Des. Devel. Ther., 2013, 7: 989-1001.

19. Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, doubleblind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther, 2008, 30(3): 499-512. PMID: 18405788. doi: 10.1016/j.clinthera.2008.03.004.

20. Moritoh Y, Takeuchi K, Asakawa T, et al. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol, 2008, 588: 325-32.

21. Asakawa T, Moritoh Y, Kataoka O, et al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR- 322), is effective in diabetic rats with sulfonylureainduced secondary failure. Life Sci, 2009, 85: 122-6.

22. Kieffer TJ, McIntosh CH, Pederson RA. Degrada￾tion of Glucosedependent Insulinotropic Polypep tide and Truncated Glucagon-like Peptide-1 in-vitro and in-vivo by Dipeptidyl Peptidase-IV. Endocrinology, 1995, 136: 3585-3596.

23. Defronzo RA, Fleck PR, Wilson CA, Mekki Q., on behalf of the Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes mellitus and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care, 2008, 31: 2315-7.

24. Kutoh E, Ukai Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug naxve type 2 diabetes: a randomized, control trial. Endocrine, 2012, 41: 435-41.

25. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q for the Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multi￾centre, randomised, double-blind, placebo-controlled study. Int. J. Clin. Pract., 2009, 63: 46-55.0

26. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes, Obesity and Metabolism, 2009, 11(2): 167-176. doi: 10.1111/j.1463-1326.2008.01016.x.

27. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia. Diabetes, Obesity and Metabolism, 2009, 11(12): 1145-1152. PMID: 19758359. doi: 10.1111/j.1463-1326.2009.01124.x.

28. Del Prato S, Camisasca R, Craig Wilson et al. Durability of the Efficacy and safety of Alogliptin Compared to Glipizide over 2 Years When Used in Combination with Metformin. Poster 66-LB presented at the 73rd Scientific Sessions of the American Diabetes Association (ADA), Chicago, Illinois, June 21-25, 2013.

29. Chrysant SG, Chrysant GS. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am. J. Cardiol., 2012, 109(11): 1681-1685.

30. Pederson RA, Kieffer TJ, Pauly R et al. The enteroinsular axis in dipeptidyl peptidase IV-negative rats. Metabolism, 1996, 45: 1335-1341.

31. Matikainen N, Taskinen MR. The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with Type 2 diabetes. Diabet. Med., 2012, 30(6): 756-757.

32. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med, 2013, 369(14): 1327-1335. PMID: 23992602. doi: 10.1056/NEJMoa1305889.

33. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med., 2013, 369(14): 1317-26.


Просмотров: 157


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)